𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia

✍ Scribed by Fredly, Hanne; Ersvær, Elisabeth; Kittang, Astrid; Tsykunova, Galina; Gjertsen, Bjørn; Bruserud, Øystein

Book ID
121626294
Publisher
Springer-Verlag
Year
2013
Tongue
English
Weight
294 KB
Volume
5
Category
Article
ISSN
1868-7075

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The histone deacetylase (HDAC) inhibitor
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia
✍ Andrea Kuendgen; Mathias Schmid; Richard Schlenk; Sabine Knipp; Barbara Hildebra 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 2 views

## Abstract ## BACKGROUND Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all‐trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro. ## METHODS We used VPA in 58 patients with acute myeloid leukemia (AML) who were too old a

Clinical trial of valproic acid and all-
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia
✍ Gesine Bug; Markus Ritter; Barbara Wassmann; Claudia Schoch; Thorsten Heinzel; K 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB 👁 2 views

## Abstract ## BACKGROUND Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induced in vitro differentiation of primary acute myeloid leukemia (AML) blasts, an effect enhanced by all‐trans retinoic acid (ATRA). Clinical responses to VPA were recently observed in patients with myelodyspl

ALL-TRANS RETINOIC ACID (ATRA) IN THE TR
ALL-TRANS RETINOIC ACID (ATRA) IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
✍ C. S. CHIM; Y. L. KWONG; R. LIANG; Y. C. CHU; C. H. CHAN; L. C. CHAN; K. F. WONG 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB 👁 2 views

Acute promyelocytic leukemia is characterized by the reciprocal translocation of chromosomes 15 and 17. All-trans retinoic acid (ATRA) efficiently induces differentiation of the abnormal promyelocytes. In this study, we had used ATRA as the primary induction therapy for 17 newly diagnosed patients,